Patent SG-11201808629U-A (SG)
Title: Immunotherapy against melanoma and other cancers
Inventor: SONNTAG ANNIKA
IPC: C12N5/0783
Filed: 2017-04-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/182395 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 38/17 (2006.01) C07K 7/06 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 39/00 (2006.01) Cl 2N 5/0783 (2010.01) (21) International Application Number: Published: PCT/EP2017/059016 — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (22) International Filing Date: claims and to be republished in the event of receipt of 13 April 2017 (13.04.2017) amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/325,773 21 April 2016 (21.04.2016) US 1606919.7 21 April 2016 (21.04.2016) GB (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tiibingen (DE). (72) Inventors: SONNTAG, Annika; BohnenbergerstraBe 9, 72076 Tiibingen (DE). WEINSCHENK, Toni; Im Mor- genrain 15, 73773 Aichwald (DE). MAHR, Andrea; Kirschenweg 22, 72076 Tiibingen (DE). SCHOOR, Oliver; Eichhaldenstrasse 19, 72074 Tiibingen (DE). FRITSCHE, Jens; Larchenweg 11, 72144 Dusslingen (DE). SINGH, Harpreet; 5122 Morningside Dr, Apt. 525, Houston, Texas 77005 (US). (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, Pettenkoferstrasse 20 - 22, 80336 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated (84) States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, protection GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, kl) ON (54) Title: IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS M ei (57) : The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In 0 1-1 0 particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated ---- T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical IN ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. © Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, f'1 soluble T-cell receptors, and other binding molecules. C